At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients With MDS
In Brief
A Phase 2 clinical trial evaluating Azacitidine and Pembrolizumab for High Risk Myelodysplastic Syndrome and 2 related conditions. Targeting 40 participants across 1 site.
Detailed Summary
This phase II trial studies the side effects of azacitidine and pembrolizumab and to see how well they work in treating patients with myelodysplastic syndrome. Azacitidine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving azacitidine and pembrolizumab may work better at treating myelodysplastic syndrome.
Study Details
Timeline
Interventions
Given IV
Given IV